失血性休克患者内皮细胞功能障碍生物标志物在复苏后持续存在
本研究为预后/流行病学Ⅱ级证据研究,纳入34例失血性休克患者(血压<90 mm Hg且≥2 U血液),在入院时、止血完成时和24小时后检测miR-19b和syndecan-1,并与轻伤患者(损伤严重度评分≤9)和对照比较。结果显示miR-19b随时间进一步升高(4.6→6.7→24.1倍变化),syndecan-1升高至42.6→50→51.5 ng/mL,两者24小时内持续显著升高并与炎症细胞因子持续升高相关。入院时syndecan-1显著预测死亡率、凝血病和大量输血,但miR-19b与syndecan-1及结局无强相关性。
要点
- 失血性休克患者入院时syndecan-1显著预测死亡率、凝血病和大量输血。
- syndecan-1在入院时、止血完成时和24小时分别为42.6→50→51.5 ng/mL,24小时内持续显著升高。
- miR-19b随时间进一步升高:入院时4.6倍→止血完成时6.7倍→24小时24.1倍变化。
- 两种生物标志物升高与炎症细胞因子持续升高相关,且独立于复苏。
- miR-19b与syndecan-1及患者结局无强相关性。
适用人群与场景
- 失血性休克患者:血压<90 mm Hg且≥2 U血液。
- 对照包括轻伤患者(损伤严重度评分≤9)和对照组。
诊断标准与关键阈值
- 失血性休克定义:血压<90 mm Hg且≥2 U血液。
- 轻伤定义:损伤严重度评分≤9。
研究设计与关键结果
- 研究类型:预后/流行病学Ⅱ级证据研究;样本量34例失血性休克患者;年龄46(19-89)岁;男性82%;穿透伤35%;损伤严重度评分24±10;24小时血制品21±19 U。
- miR-19b在入院时、止血完成时和24小时分别为4.6→6.7→24.1倍变化,轻伤患者为0.1,对照为1.2。
- syndecan-1在入院时、止血完成时和24小时分别为42.6→50→51.5 ng/mL,轻伤患者为14.7 ng/mL,对照为23.5 ng/mL。
- 两种生物标志物24小时内持续显著升高,并与炎症细胞因子持续升高相关。
- 入院时syndecan-1显著预测死亡率、凝血病和大量输血。
- miR-19b与syndecan-1及结局无强相关性。
证据类型、等级与局限
- 证据类型:预后/流行病学Ⅱ级证据研究。
- 局限:作者指出miR-19b与syndecan-1及结局无强相关性;syndecan-1随时间升高提示其在失血性休克后有多种作用,需进一步研究。
对床旁实践的改变
- 入院时syndecan-1可作为失血性休克患者死亡、凝血病和大量输血的预后标志物。
- syndecan-1和miR-19b在复苏后24小时仍持续升高,提示内皮功能障碍持续存在。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: It has been shown that microRNA-19b (miR-19b) binds to and degrades syndecan-1 after hemorrhagic shock (HS) and contributes to endothelial dysfunction in vitro and in vivo. The objective of the current study was to assess longitudinal changes in miR-19b and syndecan-1 in HS patients.
METHODS: Blood samples from HS patients (blood pressure <90 mm Hg and ≥2 U blood) were collected upon admission, completion of hemostasis, and after 24 hours for miR-19b (quantitative reverse transcription PCR) and syndecan-1 (enzyme-linked immunosorbent assay) and compared with controls and minimally injured (Injury Severity Score, ≤9). Inflammatory cytokines were measured (Luminex [Thermo Fisher, Waltham, MA]). Correlations between syndecan-1, miR-19b, inflammatory markers, and patient outcomes were performed. Logistic regression models were developed for outcomes.
RESULTS: Thirty-four HS patients were studied: age, 46 (19-89) years; male, 82%; penetrating, 35%; Injury Severity Score, 24 ± 10; and blood products at 24 hours, 21 ± 19 U. MicroRNA-19b was increased upon arrival and further increased over time: 4.6 → 6.7 → 24.1-fold change compared with 0.1 and 1.2 for minimally injured patients and controls, respectively. Syndecan-1 was increased to 42.6 → 50 → 51.5 ng/mL over time compared with 14.7 and 23.5 for minimally injured and controls, respectively. Values for both biomarkers remained significantly increased through 24 hours and were associated with a persistent increase in inflammatory cytokines. Admission syndecan-1 significantly predicted mortality, coagulopathy, and massive transfusion.
CONCLUSION: We have shown for the first time that miR-19b and syndecan-1 were biomarkers for endothelial dysfunction independent of resuscitation. MicroRNA-19b did not demonstrate a strong correlation with syndecan-1 nor outcomes. Admission syndecan-1, however, remains a strong prognostic marker, but its elevation over time suggests a versatile role following HS that requires further investigation.
LEVEL OF EVIDENCE: Prognostic/Epidemiological; Level II.
参考来源
- Zeineddin A, Wu F, Chao W, et al. Biomarkers of endothelial cell dysfunction persist beyond resuscitation in patients with hemorrhagic shock. J Trauma Acute Care Surg. 2022. PMID: 35939376. doi:10.1097/TA.0000000000003758
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。